Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: A scientific review

Southern Medical Journal

Volumn 99, Issue 3, 2006, Pages 257-273

  Insull Jr , William ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bile acid sequestrant; Cholesterol; Cholestryamine; Colesevelam HCl.; Colestipol; Combination drug therapy; Dyslipidemia; Lipid lowering; Low density lipoprotein cholesterol (LDL C)

Indexed keywords

ALPHA TOCOPHEROL; BILE ACID; BILE ACID SEQUESTRANT; CARDIAC GLYCOSIDE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; DIGOXIN; ESTROGEN; FIBRIC ACID DERIVATIVE; FUROSEMIDE; GESTAGEN; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; MEVINOLIN; NICOTINIC ACID; PENICILLIN G; PHENOBARBITAL; PHENYLBUTAZONE; PRAVASTATIN; PROPRANOLOL; QUINIDINE; TETRACYCLINE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; WARFARIN;

BILE ACID SYNTHESIS; BINDING AFFINITY; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; PATIENT COMPLIANCE; REVIEW;

ALLYLAMINE; ANTILIPEMIC AGENTS; BILE ACIDS AND SALTS; CHOLESTEROL; COLESTIPOL; DYSLIPIDEMIAS; HUMANS; LIPIDS; TREATMENT OUTCOME;

EID: 33645098531     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000208120.73327.db     Document Type: Review

References (118)

1. Iglesias P, Diez JJ. New drugs for the treatment of hypercholesterolaemia. Expert Opin Investig Drugs 2003;12:1777-1789.
2. Manhas A, Farmer JA. Hypolipidemic therapy and cholesterol absorption. Curr Atheroscler Rep 2004;6:89-93.
3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel IIIguidelines. Circulation 2004;110:227-239.
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
5. Packard CJ, Shepherd J. The hepatobiliary axis and lipoprotein metabolism: effects of bile acid sequestrants and ileal bypass surgery. J Lipid Res 1982;23:1081-1098.
6. Chiang JY. Bile acid regulation ofgene expression: roles of nuclear hormone receptors. Endocr Rev 2002;23:443-463.
7. Einarsson K, Ericsson S, Ewerth S, et al. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol 1991;40 Suppl 1:S53-S58.
8. St-Pierre MV, Kullak-Ublick GA, Hagenbuch B, et al. Transport of bile acids in hepatic and non-hepatic tissues. J Exp Biol 2001;204:1673-1686.
9. Redinger RN. The coming of age of our understanding of the enterohepatic circulation of bile salts. Am J Surg 2003;185:168-172.
10. Li-Hawkins J, Lund EG, Turley SD, et al. Disruption of the oxysterol 7alpha-hydroxylasegene in mice. J Biol Chem 2000;275:16536-16542.
11. Schwartz CC, Halloran LG, Vlahcevic ZR, et al. Preferential utilization of free cholesterol from high-density lipoproteins for biliary cholesterol secretion in man. Science 1978;200:62-64.
12. Bravo E, Cantafora A, Argiolas L. Hepatic uptake and metabolism of free cholesterol from different lipoprotein classes. An in vivo study in the rat. Biochim Biophys Acta 1989;1003:315-320.
13. Robins SJ, Fasulo JM. High density lipoproteins, but not other lipoproteins, provide a vehicle for sterol transport to bile. J Clin Invest 1997; 99:380-384.
14. Data on file.Sankyo Pharma, Inc, Parsippany, NJ, 2003.
15. Lehmann JM, Kliewer SA, Moore LB, et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 1997;272:3137-3140.
16. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 2002;99:7604-7609.
17. Miao B, Zondlo S, Gibbs S, et al. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J Lipid Res 2004;45:1410-1417.
18. Wang H, Chen J, Hollister K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999;3:543-553.
19. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999;284:1362-1365.
20. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284:1365-1368.
21. Claudel T, Sturm E, Duez H, et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 2002;109:961-971.
22. Cui J, Huang L, Zhao A, et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem 2003;278:10214-10220.
23. De Palma RG, Hubay CA, Insull W, Jr. The effect of t-tube drainage on cholesterol and bile acid metabolism in man. Surg Gynecol Obstet 1966;123:269-273.
24. DePalma RG, Levey S, Hartman PH, et al. Bile acids and serum cholesterol following T tube drainage. Arch Surg 1967;94:271-276.
25. Myant NB, Mitropoulos KA. Cholesterol 7 alpha-hydroxylase. J Lipid Res 1977;18:135-153.
26. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:: 351-364.
27. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984;69: 313-324.
28. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence ofgastrointestinal side effects. Arch Intern Med 1999; 159:1893-1900.
29. Insull WJr, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc 2001;76:971-982.
30. Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann Pharmacother 2001;35:898-907.
31. Bard JM, Parra HJ, Douste-Blazy P, et al. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition. Metabolism 1990;39:269-273.
32. WelChol (colesevelam hydrochloride) Prescribing Information v8. Sankyo Pharma Inc, Parsippany, NJ. Available at www.welchol.com. Accessed February 15, 2006.
33. Colestid (colestipol) Prescribing Information. Pharmacia & Upjohn Company, Kalamazoo, MI. Available at www.pdr.net. Accessed February 15, 2006.
34. Questran (cholestyramine) Prescribing Information. Bristol-Myers Squibb, New York, NY. Available at www.pdr.net. Accessed February 15, 2006.
35. Ast M, Frishman WH. Bile acid sequestrants. J Clin Pharmacol 1990; 30:99-106.
36. Mandeville WH, Goldberg DI. The sequestration of bile acids, a non-absorbed method for cholesterol reduction. A review. Curr Pharm Des 1997;3:15-28.
37. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003;4:779-790.
38. Holmes-Farley SR, Mandeville WH, Miller KL, et al. Colesevelam hydrochloride: synthesis and testing of a novel polymergel pharmaceutical. Polymer Prepr 2000;41:735-736.
39. Braunlin W, Zhorov E, Smisek D, et al. In vitro comparison of bile acid binding to coleseveleam HCl and other bile acid sequestrants. Polymer Prepr 2000;41:708-709.
40. Heller DP, Burke SK, Davidson DM, et al. Absorption of colesevelam hydrochloride in healthy volunteers. Ann Pharmacother 2002;36:398-403.
41. Leren TP, Hjermann I, Berg K, et al. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis 1988;73:135-141.
42. Sprecher DL, Abrams J, Allen JW, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994;120:537-543.
43. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of anti-hyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-1131.
44. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-1462.
45. Vahouny GV, Cassidy MM, Lightfoot F, et al. Ultrastructural modifications of intestinal and colonic mucosa induced by free or bound bile acids. Cancer Res 1981;41:3764-3765.
46. Nigro ND, Bhadrachari N, Chomchai C. A rat model for studying colonic cancer: effect of cholestyramine on induced tumors. Dis Colon Rectum 1973;16:438-443.
47. The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators. Arch Intern Med 1992; 152::1399-1410.
48. Gallo DG, Bailey KR, Sheffner AL. The interaction between cholestyramine and drugs. Proc Soc Exp Biol Med 1965;120:60-65.
49. Kivisto KT, Neuvonen PJ. The effect of cholestyramine and activated charcoal onglipizide absorption. Br J Clin Pharmacol 1990;30:733-736.
50. Malloy MJ, Ravis WR, Pennell AT, et al. Effect of cholestyramine resin on single dose valproate pharmacokinetics. Int J Clin Pharmacol Ther 1996;34:208-211.
51. Hunninghake DB, King S, LaCroix K. The effect of cholestyramine and colestipol on the absorption of hydrochlorothiazide. Int J Clin Pharmacol Ther Toxicol 1982;20:151-154.
52. Neuvonen PJ, Kivisto K, Hirvisalo EL. Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide. Br J Clin Pharmacol 1988;25:229-233.
53. Donovan JM, Stypinski D, Stiles MR, et al. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther 2000;14:681-690.
54. Donovan JM, Kisicki JC, Stiles MR, et al. Effect of colesevelam on lovastatin pharmacokinetics. Ann Pharmacother 2002;36:392-397.
55. Jones MR, Baker BA, Mathew P. Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. Clin Pharmacokinet 2004;43:943-950.
56. Marquis JK, Dagher R, Jones M. Dietary administration of colesevelam hydrochloride does not affect fertility or reproductive performance in rats. Int J Toxicol 2004;23:357-367.
57. Marquis JK, Dagher R, Baker BA, et al. Colesevelam hydrochloride does not cause maternal or fetal toxicity in rats and rabbits. Reprod Toxicol:in press, 2005.
58. Bergen SS Jr., Van Itallie TB, Tennent DM, et al. Effect of an anion exchange resin on serum cholesterol in man. Proc Soc Exp Biol Med 1959;102:676-679.
59. Hashim SA, VanItallie TB. Cholestyramine Resin Therapy For Hypercholesteremia: Clinical And Metabolic Studies. JAMA 1965;192:289-293.
60. Khachadurian AK. Cholestyramine therapy in patients homozygous for familial hypercholesterolemia (familial hypercholesterolemic xanthomatosis). J Atheroscler Res 1968;8:177-188.
61. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251::365-374.
62. Levy RI, Brensike JF, Epstein SE, et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation 1984;69:325-337.
63. Lamarche B, Tchernof A, Mauriege P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998;279:1955-1961.
64. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999;99: 1959-1964.
65. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis :in press, 2005.
66. Davidson MH, Toth PP. Combination therapy in the management of complex dyslipidemias. Curr Opin Lipidol 2004;15:423-431.
67. Pasternak RC, Smith SC Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002; 106:1024-1028.
68. Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med 1993;153:1321-1329.
69. Pan HY, DeVault AR, Swites BJ, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990;48:201-207.
70. Ito MK, Shabetai R. Pravastatin alone and in combination with low-dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease. Am J Cardiol 1997;80:799-802.
71. Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 2001;24:467-474.
72. Vega GL, Grundy SM. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol. JAMA 1987;257: 33-38.
73. Schrott HG, Stein EA, Dujovne CA, et al. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol 1995;75: 34-39.
74. Denke MA, Grundy SM. Efficacy of low-dose cholesterol-lowering drug therapy in men with moderate hypercholesterolemia. Arch Intern Med 1995;155:393-399.
75. Simons LA, Simons J, Parfitt A. Successful management of primary hypercholesterolaemia with simvastatin and low-dose colestipol. Med J Aust 1992;157:455-459.
76. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001;110:352-360.
77. Hunninghake D, Insull W Jr., Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001;158:407-416.
78. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypassgrafts. JAMA 1987;257:3233-3240.
79. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990;264:3013-3017.
80. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
81. Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998;82:737-743.
82. Series JJ, Gaw A, Kilday C, et al. Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia. Br J Clin Pharmacol 1990;30:49-54.
83. Weisweiler P, Schwandt P. Colestipol plus fenofibrate versus synvinolin in familial hypercholesterolaemia. Lancet 1986;2:1212-1213.
84. Barbir M, Hunt BJ, Galloway D, et al. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypassgrafting. Clin Cardiol 1994;17:59-64.
85. Houlston R, Quiney J, Watts GF, et al. Gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia. J R Soc Med 1988;81:274-276.
86. Series JJ, Caslake MJ, Kilday C, et al. Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia. Metabolism 1989;38:153-158.
87. Sommariva D, Tirrito M, Bonfiglioli D, et al. Long-term effects of bezafibrate and of a bezafibrate and cholestyramine combination on lipids and lipoprotein lipids in type IIa hypercholesterolaemic patients. Int J Clin Pharmacol Res 1986;6:249-253.
88. Curtis LD, Dickson AC, Ling KL, et al. Combination treatment with cholestyramine and bezafibrate for heterozygous familial hypercholesterolaemia. BMJ 1988;297:173-175.
89. McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin 2005;21:1403-1412.
90. Xydakis AM, Guyton JR, Chiou P, et al. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol 2004;94:795-797.
91. Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am J Ther :in press, 2005.
92. Dorr AE, Gundersen K, Schneider JC Jr., et al Colestipol hydrochloride in hypercholesterolemic patients-effect on serum cholesterol and mortality. J Chronic Dis 1978;31:5-14.
93. Stone NJ. Cholesterol, colestipol and coronary heart disease. J Chronic Dis 1978;31:1-3.
94. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-569.
95. The Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypassgrafts. N Engl J Med 1997;336:153-162.
96. Niaspan (niacin extended release tablets) Prescribing Information. Kos Pharmaceuticals, Inc, Cranbury, NJ. Available at: http://www.niaspan. com. Accessed February 15, 2006.
97. Brown BG, Brockenbrough A, Zhao X-Q, et al. Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year Familial Atherosclerosis Treatment Study (FATS) follow-up. Circulation 1998;98:1-635 (abstract 3341).
98. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-3012.
99. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005;142:95-104.
100. Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005;165:725-730.
101. Waters DD, Azar RR Should intensive cholesterol lowering play a role in the management of acute coronary syndromes? Am J Cardiol 2000; 86:35J-42J (discussion 42J-43J).
102. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterolgoals. Arch Intern Med 2000;160: 459-467.
103. Brown BG, Bardsley J, Poulin D, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol 1997;80:111-115.
104. Malloy MJ, Kane JP, Kunitake ST, et al. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med 1987;107:616-623.
105. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994;121:416-422.
106. Steffensen KR, Gustafsson JA. Putative metabolic effects of the liver X receptor (LXR). Diabetes 2004;53 Suppl 1:S36-S42.
107. Stulnig TM, Oppermann U, Steffensen KR, et al. Liver X receptors downregulate 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. Diabetes 2002;51:2426-2433.
108. Laffitte BA, Chao LC, Li J, et al. Activation of liver X receptor improvesglucose tolerance through coordinate regulation ofglucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 2003; 100:5419-5424.
109. Ou J, Tu H, Shan B, et al. Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c)gene by antagonizing ligand-dependent activation of the LXR. Proc Natl Acad Sci U S A 2001;98:6027-6032.
110. Dawson PA. Bile secretion and the enterohepatic circulation of bile acids. In: Feldman M, Friedman LS, Sleisenger MH. eds. Gastrointestinal and Liver Disease, 7th ed. Philadelphia, Saunders, 2002, pp 1051-1064.
111. Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999;159:2647-2658.
112. RedBook Drug Topics, 108th ed. Stamford, CT: Thomson Healthcare, 2004.
113. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III. JAMA 1998;260:359-366.
114. Hunninghake DB, Stein EA, Bremner WF, et al. Dose-Response Study of Colestipol Tablets in Patients with Moderate Hypercholesterolemia. Am J Ther 1995;2:180-189.
115. Wierzbicki AS, Lumb PJ, Semra Y, et al. Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. QJM 1999;92:387-394.
116. Sacks FM, Pasternak RC, Gibson CM, et al. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet 1994;344:1182-1186.
117. Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875-883.
118. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323:946-955.